Evidence map›Paper›PMID 28688843›Full record

ArticleJournal of pharmaceutical sciences2017

Chemical Stability of the Botanical Drug Substance Crofelemer: A Model System for Comparative Characterization of Complex Mixture Drugs.

Asha Hewarathna, Olivier Mozziconacci, Maulik K Nariya, Peter A Kleindl, Jian Xiong, Adam C Fisher, Sangeeta B Joshi, C Russell Middaugh, M Laird Forrest, David B Volkin and 2 more

Abstract readComparative Study
In one paragraph

Article in Journal of pharmaceutical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Asha HewarathnaDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047.
Olivier MozziconacciDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047.
Maulik K NariyaDepartment of Physics and Astronomy, University of Kansas, Lawrence, Kansas 66047.
Peter A KleindlDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047.
Jian XiongDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047; Macromolecule and Vaccine Stabilization Center, University of Kansas, Lawrence, Kansas 66047.
Adam C FisherCenter for Drug Evaluation and Research, Office of Pharmaceutical Quality, U.S. Food and Drug Administration, Silver Spring, Maryland 20993.
Sangeeta B JoshiDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047; Macromolecule and Vaccine Stabilization Center, University of Kansas, Lawrence, Kansas 66047.
C Russell MiddaughDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047; Macromolecule and Vaccine Stabilization Center, University of Kansas, Lawrence, Kansas 66047.
M Laird ForrestDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047.
David B VolkinDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047; Macromolecule and Vaccine Stabilization Center, University of Kansas, Lawrence, Kansas 66047.
Eric J DeedsCenter for Computational Biology, University of Kansas, Lawrence, Kansas 66047; Department of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66047; Santa Fe Institute, Santa Fe, New Mexico 87501.
Christian SchöneichDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047. Electronic address: schoneic@ku.edu.

Funding

Biomaterials for treatment of head and neck cancerR01CA173292 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI FORREST, MARCUS LAIRD · 2013 to 2017
$1.4M
Development of an Integrated Mathematical Model for Comparative Characterization of Complex MoleculeU01FD005285 · FDA · UNIVERSITY OF KANSAS LAWRENCE · PI FORREST, MARCUS LAIRD, MIDDAUGH, CHARLES RUSSELL · 2014 to 2016
$1.0M
FDA HHS U01 FD005285NCI NIH HHS R01 CA173292
6 · The paper itself

Abstract

As the second of a 3-part series of articles in this issue concerning the development of a mathematical model for comparative characterization of complex mixture drugs using crofelemer (CF) as a model compound, this work focuses on the evaluation of the chemical stability profile of CF. CF is a biopolymer containing a mixture of proanthocyanidin oligomers which are primarily composed of gallocatechin with a small contribution from catechin. CF extracted from drug product was subjected to molecular weight-based fractionation and thiolysis. Temperature stress and metal-catalyzed oxidation were selected for accelerated and forced degradation studies. Stressed CF samples were size fractionated, thiolyzed, and analyzed with a combination of negative-ion electrospray ionization mass spectrometry (ESI-MS) and reversed-phase-HPLC with UV absorption and fluorescence detection. We further analyzed the chemical stability data sets for various CF samples generated from reversed-phase-HPLC-UV and ESI-MS using data-mining and machine learning approaches. In particular, calculations based on mutual information of over 800,000 data points in the ESI-MS analytical data set revealed specific CF cleavage and degradation products that were differentially generated under specific storage/degradation conditions, which were not initially identified using traditional analysis of the ESI-MS results.

Indexed as

AntidiarrhealsChromatography, High Pressure LiquidDrug StabilityDrug StorageMachine LearningOxidation-ReductionProanthocyanidinsSpectrometry, Mass, Electrospray IonizationSulfhydryl CompoundsTemperatureAntidiarrhealscrofelemerProanthocyanidinsSulfhydryl Compoundschemical stabilitycomplex mixturecrofelemerHPLCmachine learningmass spectrometrymutual information scoresoxidation

Identifiers

PMID28688843
PMCPMC6644711

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.